GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (TSXV:HEM) » Definitions » Cyclically Adjusted PB Ratio

Hemostemix (TSXV:HEM) Cyclically Adjusted PB Ratio : (As of Jun. 02, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Hemostemix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hemostemix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Hemostemix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix Cyclically Adjusted PB Ratio Chart

Hemostemix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.23 0.84 -

Hemostemix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.84 - - -

Competitive Comparison of Hemostemix's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Hemostemix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemostemix's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Hemostemix's Cyclically Adjusted PB Ratio falls into.


;
;

Hemostemix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Hemostemix's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Hemostemix's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.051/127.3637*127.3637
=-0.051

Current CPI (Dec. 2024) = 127.3637.

Hemostemix Quarterly Data

Book Value per Share CPI Adj_Book
201412 0.971 98.367 1.257
201503 0.732 99.789 0.934
201506 0.464 100.500 0.588
201509 0.196 100.421 0.249
201512 0.048 99.947 0.061
201603 -0.143 101.054 -0.180
201606 -0.316 102.002 -0.395
201609 -0.602 101.765 -0.753
201612 -0.952 101.449 -1.195
201703 -0.707 102.634 -0.877
201706 -0.835 103.029 -1.032
201709 0.364 103.345 0.449
201712 0.326 103.345 0.402
201803 0.279 105.004 0.338
201806 0.208 105.557 0.251
201809 0.129 105.636 0.156
201812 0.032 105.399 0.039
201903 -0.043 106.979 -0.051
201906 -0.115 107.690 -0.136
201909 -0.199 107.611 -0.236
201912 -0.269 107.769 -0.318
202003 -0.077 107.927 -0.091
202006 -0.072 108.401 -0.085
202009 -0.106 108.164 -0.125
202012 -0.020 108.559 -0.023
202103 -0.028 110.298 -0.032
202106 -0.029 111.720 -0.033
202109 -0.038 112.905 -0.043
202112 -0.089 113.774 -0.100
202203 -0.081 117.646 -0.088
202206 -0.065 120.806 -0.069
202209 -0.052 120.648 -0.055
202212 -0.089 120.964 -0.094
202303 -0.086 122.702 -0.089
202306 -0.082 124.203 -0.084
202309 -0.079 125.230 -0.080
202312 -0.085 125.072 -0.087
202406 -0.096 127.522 -0.096
202409 -0.099 127.285 -0.099
202412 -0.051 127.364 -0.051

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hemostemix  (TSXV:HEM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Hemostemix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Hemostemix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemostemix Business Description

Industry
Traded in Other Exchanges
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.
Executives
Thomas Smeenk Director
Peter Alan Lacey Director
Loran Swanberg Director
Blake Wood 10% Security Holder
Ravi Jain Senior Officer

Hemostemix Headlines

No Headlines